CTLA4 and cancer: However, CTLA‐4 binds to CD80 and CD86 with stronger affinity inhibiting the activation of T cells, thereby weakening the antitumor immunity.[150] To effectively treat cancer, monoclonal antibodies against PD‐1, PD‐L1, and CTLA‐4 have been used in clinical practice with remarkable results.